IDH1 and central nervous system cancer: Research in the field has to deal with intrinsic complexity and heterogeneity, taking into account the different molecular subtypes of gliomas (e.g., IDH wild type vs. mutation), grading (low- and high grade), classification in use, and typologies of therapies.